Insights

Making sense of chaos in the GLP-1 space

Inside a Promise Pharmacy compounded tirzepatide shipment: the cold chain, the contents of the vial, the BUD, and how to reach a pharmacist.

One patient shares her real Shed experience: $299 becomes $598, the cancel button is disabled, and a required video visit appears only after you pay.

A new patent covers a fizzy tablet meant to carry GLP-1 medicine past your stomach. See how it would work and how early it really is.

Oral GLP-1s are taking real market share. See the weight loss numbers side by side and where a pill or a shot genuinely fits better.

A study found 15 cases of a rare B1 deficiency brain injury in GLP-1 users. See what the data shows and the warning sign 13 of them had first.

A patient unboxes compounded tirzepatide dispensed by The Pharmacy Hub and compounded by BPI Labs: cooler, gel pack, 4 mL vial, labels, storage card.

Three diagnoses disqualify you from Medicare's $50 GLP-1 price. See why, what a Part D copay really costs, and how cash pay compares.

Most peptides in a wellness stack have zero human trials. See what the research shows, and the 12-year gap five basic habits produced.

SB 1089 passed the California Legislature and awaits the governor. See what it actually does, what it does not do, and what to watch next.

An Australian lab tested 18 vials sold as retatrutide. One matched its label. See what the dosing errors were and why a purity test proves little.

Patient shares his real Belle experience: flat $249 compounded tirzepatide, no membership fee, 4-day UPS delivery, easy canceling. See pros and cons.

PCOS was renamed PMOS in 2026. See what the pooled randomized evidence on GLP-1s actually found, and why a PMOS diagnosis will not unlock coverage.